Skip to main content

Table 2 Comparisons of NLRC4 methylation levels between cases and controls

From: NLRC4 methylation and its response to intravenous immunoglobulin therapy in Kawasaki disease: a case control study

Terms

Characteristics

Case

Control

p value*

All

All

44

51

 

Month Age

42.28 ± 4.68

51.35 ± 2.02

0.081

CpG1(%)

41.46 ± 2.63

56.84 ± 1.48

2.93E-06

CpG2(%)

39.49 ± 2.32

51.64 ± 1.35

2.35E-05

CpG3(%)

37.36 ± 2.39

50.68 ± 1.30

6.46E-06

CpG4(%)

44.45 ± 2.91

61.45 ± 1.56

2.47E-06

CpG5(%)

31.58 ± 1.93

42.24 ± 1.22

1.26E-05

Means methylation(%)

38.87 ± 2.43

52.57 ± 1.35

5.42E-06

Age

≤ 36 months

24

10

 

CpG1(%)

49.98 ± 3.62

65.42 ± 1.93

0.00069

CpG2(%)

46.86 ± 3.24

59.85 ± 1.55

0.00107

CpG3(%)

45.42 ± 3.29

58.358 ± 1.80

0.00163

CpG4(%)

54.31 ± 3.87

70.749 ± 2.646

0.00137

CpG5(%)

37.62 ± 2.71

49.89 ± 1.938

0.00087

Means methylation(%)

46.84 ± 3.33

60.85 ± 1.88

0.00091

> 36 months

20

41

 

CpG1(%)

31.24 ± 2.32

54.75 ± 1.62

7.98E-15

CpG2(%)

30.65 ± 1.99

49.63 ± 1.48

8.98E-13

CpG3(%)

27.68 ± 1.93

48.81 ± 1.408

1.13E-15

CpG4(%)

32.62 ± 2.71

59.186 ± 1.653

1.62E-16

CpG5(%)

24.32 ± 1.65

40.373 ± 1.28

2.02E-12

Means methylation(%)

29.30 ± 2.09

50.55 ± 1.45

5.49E-15

Gender

Male

31

46

 

CpG1(%)

43.98 ± 3.49

58.26 ± 1.38

4.87E-04

CpG2(%)

41.62 ± 3.09

52.77 ± 1.33

0.002

CpG3(%)

39.89 ± 3.14

51.85 ± 1.25

0.001

CpG4(%)

47.55 ± 3.80

62.75 ± 1.54

6.40E-04

CpG5(%)

33.21 ± 2.57

43.18 ± 1.20

0.001

Means methylation(%)

41.25 ± 3.21

53.76 ± 1.30

8.38E-04

Female

13

5

 

CpG1(%)

35.47 ± 2.66

43.85 ± 5.77

0.15

CpG2(%)

34.43 ± 2.31

41.20 ± 4.28

0.156

CpG3(%)

31.32 ± 2.48

39.92 ± 4.57

0.098

CpG4(%)

37.05 ± 3.14

49.49 ± 4.94

0.052

CpG5(%)

27.67 ± 1.95

33.54 ± 4.37

0.172

Means methylation(%)

33.19 ± 2.49

41.60 ± 4.71

0.108

  1. * The p value less than or equal to 0.05 is in bold